Laboratory of Nanomedicine and Targeted Delivery

Lab of nanomedicine and targeted delivery is thoughtfully designed to promote the development of innovative therapeutic solutions, with a primary emphasis on creating biomimetic hybrid lipid-polymer nanoparticles aimed at enhancing combinatorial therapy for colorectal cancer. This laboratory is part of the Faculty of Medicine at the University of Talca and plays a crucial role in the Center for Nanomedicine Diagnostic & Drug Development (ND3).

VilosLab | LNTD- Laboratorio de nanomedicina y liberación dirigida Talca Chile Universidad de Talca

Research

Our research at the Laboratory of Nanomedicine Targeted Delivery is at the forefront of nanomedicine, structured around three pivotal areas: targeted nanotherapeutics, nano-bio interactions, and combination therapy for colorectal cancer. We specialize in advanced formulation techniques like emulsions, self-assembly, and microfluidics to improve drug delivery systems that enhance intracellular release, solubility, and co-delivery of therapeutics, tailored to target specific cells or tissues. Additionally, we explore the intricate dynamics between nanomaterials and biological systems, particularly focusing on the interactions with cellular membranes and the role of phospholipids to ensure biocompatibility and effective therapeutic outcomes. Our third focus area utilizes these nanotechnologies to develop combination therapies for colorectal cancer, emphasizing precision in drug release to improve treatment efficacy. Collectively, these efforts are aimed at transforming patient care by developing safer, more effective, and targeted therapeutic approaches

TEM image of hubrid lipid-polymer nanoparticles

Advancements in Targeted Nanotherapeutics

1. Nanotherapeutics; 2. Targeted Drug Delivery; 3. Formulation Methods

This line of research focuses on developing nanotherapeutics using various formulation methods, such as emulsions, self-assembly, and microfluidics, to enhance intracellular release of macromolecules, improve solubility of poorly water-soluble drugs, and facilitate the co-delivery of therapeutic agents. Additionally, we explore targeting strategies to direct these nanotherapeutics toward specific cells or tissues, significantly contributing to the advancement of targeted drug delivery systems that are crucial for innovative treatments across various medical fields.

Nano-Bio Interactions and Advanced Materials

1. Hybrid Nanoparticles; 2. Phospholipid Composition; 3. Biological Interactions

This line of research investigates the intricate interactions between nanomaterials and biological systems, with a specific emphasis on their engagement with cell membranes, particularly the role of phospholipid composition. By utilizing hybrid lipid-polymer nanoparticles that closely resemble biological membranes, these materials are essential for the dynamic and efficient delivery of therapeutics throughout the human body. Furthermore, the research explores how these nanomaterials interact with blood components, which is vital for comprehending their behavior and effectiveness in a biological context. Together, these studies lay a foundational understanding of how nanomaterials impact biological processes at the cellular level.

Combined Therapy for Colorectal Cancer

1. Nanopharmacology; 2. Combination Therapy; 3.Colorectal Cancer

This research focuses on enhancing the efficacy of chemotherapeutic agents in colorectal cancer through innovative combination therapy strategies. By investigating critical intracellular pathways that influence cancer cell survival, the study aims to identify potential therapeutic targets. Central to this work is the exploration of engineered nanoscale drug delivery systems that enable precise and controlled release, ultimately improving treatment outcomes and safety. Dr. Vilos also examines the pharmacological effects of combined therapies encapsulated in nanoparticles, as well as the regulatory pathways necessary for translating these cutting-edge nanomedicine technologies from the laboratory to clinical practice. This comprehensive approach seeks to advance therapeutic options for colorectal cancer, fostering improved patient outcomes and paving the way for more effective treatments.